Skip to content
PubMed This is a summary of 15 peer-reviewed journal articles Updated
Oncology · Capillary Leak Syndrome

How Is Capillary Leak Syndrome Managed During Tagraxofusp?

At a Glance

Suspected Capillary Leak Syndrome during tagraxofusp treatment needs urgent medical attention. Doctors usually pause the drug, monitor blood pressure, weight, protein levels, breathing, and urine output, then tailor treatment to severity; tagraxofusp resumes only when symptoms and results are safe.

If you start rapidly gaining weight, developing swelling (edema), experiencing drops in blood pressure, or having trouble breathing during tagraxofusp therapy, your medical team will act quickly to manage a potential complication called Capillary Leak Syndrome (CLS) [1]. CLS is a severe condition where fluid and proteins leak from your blood vessels into surrounding tissues [1]. Because CLS can be life-threatening and carries a boxed warning on the tagraxofusp label, it is treated as a medical emergency requiring strict monitoring [2][3]. While most cases occur during the first cycle of treatment, CLS can happen during any cycle, so vigilance is always required [1].

What to Do If You Notice Symptoms at Home

Do not wait for your next scheduled appointment or the next day’s weight check if you suspect CLS.

  • Immediate Action: Call your oncology team’s 24/7 emergency number immediately if you experience sudden or rapidly worsening swelling, unexpected rapid weight gain, dizziness, fainting, or significantly reduced urine output [2].
  • Call Emergency Services (911): If you experience severe symptoms like shortness of breath, chest pain, or confusion, seek emergency medical care immediately [4].
  • Never Self-Treat: Do not attempt to manage swelling with extra fluids or by taking over-the-counter water pills (diuretics) without explicit instruction from your care team [5].

How the Hospital Manages CLS

If CLS is suspected, the immediate response is to hold or stop your tagraxofusp infusions [6]. You will be closely monitored; while mild cases might be managed in a standard oncology ward, severe cases or patients with breathing and kidney complications may require transfer to an Intensive Care Unit (ICU) [5][3].

Treatment is highly individualized based on your blood pressure, circulating fluid volume, and kidney function. There is no one-size-fits-all package, but the hospital may use specific therapies to stabilize you:

  • Albumin Infusions: Because CLS causes your body to lose albumin (a key blood protein) into the tissues, doctors may provide IV albumin to help pull fluid back into your blood vessels and stabilize your blood volume [7][5].
  • Cautious Fluid Replacement: Doctors must be very careful with standard IV fluids. Giving too much can worsen tissue swelling and cause fluid to build up in your lungs (pulmonary edema) [5][8].
  • Vasopressors: If your blood pressure remains dangerously low, you may be given vasopressors—medications that tighten your blood vessels to help safely raise your blood pressure [9][10].
  • Intravenous Steroids: In some cases, corticosteroids may be administered through an IV to help reduce the inflammation associated with the leaky blood vessels [11][12].
  • Diuretics (Water Pills): Once your blood pressure is stabilized and the leaking stops, the fluid trapped in your tissues will return to your bloodstream. At this specific stage, doctors may use diuretics to help your kidneys flush the extra fluid out as urine, preventing fluid overload [13]. Diuretics are only used when clinically indicated, as using them too early can dangerously worsen low blood pressure [4].
  • Advanced Support: In severe cases where fluid buildup heavily impacts lung or kidney function, patients may require oxygen, breathing assistance, or renal replacement therapy (a form of dialysis that may or may not be temporary) to clear the fluid safely [4][14].

When Can Treatment Resume?

Stopping the drug is only the first step. Tagraxofusp will not automatically be restarted just because you feel better [6]. The decision to resume therapy depends on strict, label-based criteria and requires that your CLS symptoms have resolved and your weight, blood pressure, and serum albumin levels have returned to safe baselines [15][6].

Before any future doses, your care team will continue to rigorously check your serum albumin, weight, and other health markers [7]. Depending on the severity of the CLS episode, your doctor may decide to permanently discontinue tagraxofusp to ensure your safety [15].

Common questions in this guide

What should I do if I notice possible CLS while receiving tagraxofusp?
Call your oncology team’s 24/7 emergency number immediately if you have sudden swelling, rapid weight gain, dizziness, fainting, or much less urine. Call emergency services for severe shortness of breath, chest pain, or confusion, and do not take extra fluids or diuretics unless your care team tells you to.
Does Capillary Leak Syndrome happen only during the first tagraxofusp cycle?
Most cases occur during the first cycle, but CLS can develop during any cycle of tagraxofusp treatment. Continue monitoring your weight and symptoms throughout therapy and follow the emergency plan from your oncology team.
How do doctors treat CLS caused by tagraxofusp?
Doctors usually hold or stop tagraxofusp and closely monitor blood pressure, fluid balance, albumin, kidney function, and breathing. Depending on severity, treatment may include albumin infusions, carefully controlled intravenous fluids, medicines to raise blood pressure, steroids, diuretics after blood pressure stabilizes, oxygen, breathing support, or dialysis.
When can tagraxofusp be restarted after CLS?
Tagraxofusp is considered for restart only after CLS symptoms have resolved and your weight, blood pressure, and blood albumin level have returned to safe baseline values. The decision follows treatment-label criteria and may be delayed or replaced by permanent discontinuation after a severe episode.
Why are weight and albumin checked before tagraxofusp doses?
Rapid weight gain can signal fluid leaking into tissues, while a low albumin level can indicate loss of an important blood protein during CLS. Checking these results before doses helps the oncology team judge whether treatment is safe to give.
Can I take a water pill for swelling during tagraxofusp therapy?
Do not take a diuretic on your own for suspected CLS. Doctors may use one only after blood pressure is stable and the leak has stopped, because using it too early can worsen dangerously low blood pressure.

Questions For You

Answer a question to get research tailored to you. Your answers are private.

Get notified when new evidence is published on Blastic plasmacytoid dendritic cell neoplasm.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.What are my specific weight gain or albumin level thresholds that should prompt me to call the emergency number immediately?
  2. 2.Do you check my serum albumin levels and weight right before every single tagraxofusp dose?
  3. 3.If my treatment is paused due to CLS, what specific clinical and laboratory criteria must be met before it is considered safe to restart?
  4. 4.Under what circumstances would a CLS episode mean I must permanently stop taking tagraxofusp?

References

References (15)
  1. 1

    Optimizing capillary leak syndrome prevention and management in patients receiving tagraxofusp for blastic plasmacytoid dendritic cell neoplasm.

    Lane AA, Papayannidis C, Angelucci E, et al.

    Leukemia & lymphoma 2025; (66(14)):2569-2577 doi:10.1080/10428194.2025.2557505.

    PMID: 41134616
  2. 2

    Care Optimization for Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm Receiving Tagraxofusp.

    Faysman K, Rubin J, Lubas A, et al.

    Journal of the advanced practitioner in oncology 2025; 1-14 doi:10.6004/jadpro.2025.16.7.21.

    PMID: 40787154
  3. 3

    Long-Term Benefits of Tagraxofusp for Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm.

    Pemmaraju N, Sweet KL, Stein AS, et al.

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2022; (40(26)):3032-3036 doi:10.1200/JCO.22.00034.

    PMID: 35820082
  4. 4

    Sorafenib-Induced Capillary Leak Syndrome.

    Kwon H, Odackal J, Husain M, Liebner DA

    Case reports in oncology 2023; (16(1)):1087-1094 doi:10.1159/000533957.

    PMID: 37900814
  5. 5

    Handling shock in idiopathic systemic capillary leak syndrome (Clarkson's disease): less is more.

    Wu MA, Colombo R, Podda GM, Cicardi M

    Internal and emergency medicine 2019; (14(5)):723-730 doi:10.1007/s11739-019-02113-4.

    PMID: 31154613
  6. 6

    Tagraxofusp Treatment: Implications for Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm.

    Morin A, Kechedjian F, Walton P, Tavakoli A

    Clinical journal of oncology nursing 2021; (25(2)):E10-E16 doi:10.1188/21.CJON.E10-E16.

    PMID: 33739343
  7. 7

    Tagraxofusp and anti-CD123 in blastic plasmacytoid dendritic cell neoplasm: a new hope.

    Cangini D, Silimbani P, Cafaro A, et al.

    Minerva medica 2020; (111(5)):467-477 doi:10.23736/S0026-4806.20.07018-4.

    PMID: 32955827
  8. 8

    Capillary leak syndrome: etiologies, pathophysiology, and management.

    Siddall E, Khatri M, Radhakrishnan J

    Kidney international 2017; (92(1)):37-46 doi:10.1016/j.kint.2016.11.029.

    PMID: 28318633
  9. 9

    Recognition and management of idiopathic systemic capillary leak syndrome: an evidence-based review.

    Baloch NU, Bikak M, Rehman A, Rahman O

    Expert review of cardiovascular therapy 2018; (16(5)):331-340 doi:10.1080/14779072.2018.1456920.

    PMID: 29564922
  10. 10

    [Idiopathic and secondary capillary leak syndromes: A systematic review of the literature].

    Duron L, Delestre F, Amoura Z, Arnaud L

    La Revue de medecine interne 2015; (36(6)):386-94.

    PMID: 25600329
  11. 11

    Systemic Capillary Leak Syndrome (Clarkson Syndrome) in Cancer Patients: A Systematic Review.

    Shin JI, Lee KH, Lee IR, et al.

    Journal of clinical medicine 2018; (7(11)) doi:10.3390/jcm7110418.

    PMID: 30404164
  12. 12

    Nivolumab-induced systemic capillary leak syndrome as an ultra rare life-threatening phenomenon of late toxicity and intravenous immunoglobulin efficacy.

    Polishchuk I, Yakobson A, Zemel M, et al.

    Immunotherapy 2021; (13(10)):807-811 doi:10.2217/imt-2020-0335.

    PMID: 33969699
  13. 13

    Renal Replacement Therapy in Idiopathic Systemic Capillary Leak Syndrome: A Case Report.

    Tokutake M, Nakazawa A, Ota M

    Cureus 2024; (16(2)):e53982 doi:10.7759/cureus.53982.

    PMID: 38476796
  14. 14

    Systemic Capillary Leak Syndrome as a Rare, Potentially Fatal Complication of COVID-19: A Case Report and Literature Review.

    Naito S, Yamaguchi H, Hagino N

    Cureus 2023; (15(8)):e42837 doi:10.7759/cureus.42837.

    PMID: 37664276
  15. 15

    Tagraxofusp, the first CD123-targeted therapy and first targeted treatment for blastic plasmacytoid dendritic cell neoplasm.

    Economides MP, McCue D, Lane AA, Pemmaraju N

    Expert review of clinical pharmacology 2019; (12(10)):941-946 doi:10.1080/17512433.2019.1662297.

    PMID: 31465247

This page is for informational purposes only and does not constitute medical advice. If you are receiving tagraxofusp and develop possible CLS symptoms, contact your oncology team or emergency services immediately.